| Stereochemistry | ABSOLUTE |
| Molecular Formula | C29H36O4 |
| Molecular Weight | 448.5937 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)CC[C@]5(C)[C@@]4([H])CC[C@]3(C)[C@@]1(O[C@@](C)(O2)C6=CC=CC=C6)C(C)=O
InChI
InChIKey=AHBKIEXBQNRDNL-FVCOMRFXSA-N
InChI=1S/C29H36O4/c1-18(30)29-25(32-28(4,33-29)19-8-6-5-7-9-19)17-24-22-11-10-20-16-21(31)12-14-26(20,2)23(22)13-15-27(24,29)3/h5-9,16,22-25H,10-15,17H2,1-4H3/t22-,23+,24+,25-,26+,27+,28-,29-/m1/s1
| Molecular Formula | C29H36O4 |
| Molecular Weight | 448.5937 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Algestone acetophenide, also known as dihydroxyprogesterone acetophenide, is an agonist of the progesterone receptor. Algestone acetophenide in combination with estradiol enanthate is sold under the brand name Deladroxate as a form of long-lasting injectable birth control. The combination provides simultaneously prolonged progestational and estrogenic activities both of which are maintained at effective levels for approximately three weeks after the intramuscular injection of a single dose.
Approval Year
PubMed
Sample Use Guides
On the eight day (7th-9th) after the onset of menstruation from the last ovulatory cycle, one ml.of Deladroxate (150 mg of dihydroxyprogesterone acetophenide combined with 10 mg of estradiol enanthate) was injected intramuscularly in the deltoid or gluteal region.
Route of Administration:
Intramuscular
